Immediate Impact
73 standout
Citing Papers
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
2023 Standout
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
2022 Standout
Works of R Holman being referenced
Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| R Holman | 20 | 57 | 58 | 60 | 6 | 93 | |
| S Arslanian | 11 | 64 | 39 | 65 | 8 | 167 | |
| Anette-Gabriele Ziegler | 23 | 89 | 96 | 83 | 7 | 145 | |
| Hugo Fitipaldi | 17 | 51 | 54 | 27 | 6 | 133 | |
| Noémie Dubois | 43 | 55 | 21 | 54 | 8 | 175 | |
| C. Tortul | 12 | 83 | 80 | 97 | 6 | 202 | |
| D Humphriss | 26 | 96 | 32 | 40 | 6 | 168 | |
| Frederick T. J. Lin | 11 | 33 | 27 | 51 | 4 | 221 | |
| Claire Morbey | 3 | 131 | 46 | 64 | 4 | 169 | |
| Mauro Giuliani | 27 | 68 | 61 | 132 | 8 | 180 | |
| Maria Teresa Martínez Larrad | 5 | 43 | 92 | 39 | 4 | 190 |
All Works
Loading papers...